The gut drug behind a growing epidemic of bone fractures is not some obscure experimental medication. It is the proton pump inhibitor, or PPI — one of the most widely prescribed drug classes in the world, sold under familiar names like Nexium, Prilosec, Prevacid, and Protonix. In May 2010, the FDA revised all prescription and over-the-counter PPI labels to warn of an increased risk of fractures of the hip, wrist, and spine, particularly in patients taking high doses or using the drugs for a year or more. Meta-analyses have since quantified the damage: a 45 percent increased risk of hip fracture, a 60 percent increased risk of spine fracture, and an 18 percent increased risk of fracture at any site. For the millions of older adults already vulnerable to falls and cognitive decline, these numbers represent a quiet but serious public health problem.
What makes this story especially troubling is the sheer scale of PPI use. Over 15 million Americans hold active PPI prescriptions, and approximately 100 million PPI prescriptions are dispensed annually in the United States. Omeprazole alone was the eighth most commonly prescribed medication in the country in 2019, with over 52 million prescriptions that year. Yet studies estimate that up to 70 percent of PPI users take them without an appropriate medical indication — meaning millions of people are absorbing the risks of these drugs for heartburn they could manage with dietary changes, antacids, or shorter treatment courses. This article examines how PPIs damage bone, why the problem matters so much for people with dementia and their caregivers, and what practical steps can reduce the danger.
Table of Contents
- How Do Proton Pump Inhibitors Cause an Epidemic of Bone Fractures?
- What the FDA Warning Actually Says — and What It Leaves Out
- The Dementia Connection — Why PPI-Related Fractures Hit Harder in Aging Brains
- Safer Alternatives and How to Weigh the Tradeoffs
- The Litigation Landscape and What It Tells Us About Risk
- What Caregivers Should Ask at the Next Doctor’s Visit
- Where the Science Is Headed
- Conclusion
- Frequently Asked Questions
How Do Proton Pump Inhibitors Cause an Epidemic of Bone Fractures?
PPIs work by shutting down the acid-producing pumps in the stomach lining. That is exactly what you want when treating a bleeding ulcer or severe gastroesophageal reflux disease. But stomach acid is not just a digestive inconvenience — it is necessary to absorb calcium. When acid production is chronically suppressed, calcium absorption drops, and the body begins pulling calcium from the one place it has reserves: the skeleton. Over months and years, this slow withdrawal weakens bone density in ways that standard checkups rarely catch until a fracture occurs. The calcium pathway is not the only mechanism researchers have identified. Chronic PPI use triggers hypergastrinemia, an overproduction of the The FDA’s 2010 safety communication was based on a review of seven epidemiological studies. Two of those studies showed that fracture risk increased with higher PPI doses, and two showed risk increased with longer duration of use. The agency required new label warnings for both prescription and OTC versions, making this one of the more significant post-market safety actions for a class of drugs that had been considered largely benign. However, the FDA stopped short of pulling OTC PPIs from shelves or restricting prescriptions, leaving the responsibility with physicians and patients. What the warning does not fully convey is how difficult it is to stop taking PPIs once you have started. Abrupt discontinuation often triggers rebound acid hypersecretion — a surge of stomach acid that feels worse than the original symptoms. Patients who try to quit frequently give up within days and resume the medication, sometimes at higher doses. This creates a cycle that extends PPI use well beyond the recommended eight-to-twelve-week course. If you or someone you care for has been on a PPI for more than a year, do not stop cold turkey without medical guidance. A gradual taper, sometimes combined with an H2 blocker like famotidine, is generally the safer path. But be aware: even with a taper, the transition can be uncomfortable, and not every physician is experienced in managing PPI withdrawal. For people living with dementia or mild cognitive impairment, a bone fracture is not just an orthopedic event. It is a cognitive one. Hip fractures in dementia patients carry a mortality rate roughly double that of cognitively intact adults, and survivors frequently experience a permanent step-down in function. A person with moderate Alzheimer’s who was still dressing and feeding independently before a hip fracture may emerge from the hospital unable to do either. The anesthesia, pain medications, unfamiliar environment, and immobility all conspire to accelerate decline. PPIs add another layer of concern. A 2025 systematic review published in the European Journal of Clinical Pharmacology reaffirmed the association between chronic PPI use and not only increased fracture risk but also elevated dementia risk. The biological plausibility is there: impaired B12 absorption, disrupted magnesium levels, and altered gut microbiota all have documented effects on neurological function. For a caregiver managing a loved one’s medication list, the PPI prescribed years ago for occasional heartburn may be quietly contributing to both skeletal fragility and cognitive erosion. The combination is particularly cruel — weaker bones and a brain less equipped to prevent falls or navigate recovery. Not everyone on a PPI can simply switch to something else. If you have Barrett’s esophagus, severe erosive esophagitis, or Zollinger-Ellison syndrome, PPIs may be genuinely necessary, and the fracture risk must be weighed against the risk of esophageal damage or cancer. In those cases, the goal is to use the lowest effective dose and to supplement with calcium and vitamin D under medical supervision. For the estimated 70 percent of PPI users who lack a strong medical indication, the alternatives deserve serious consideration. H2 receptor blockers like famotidine (Pepcid) reduce acid without completely shutting down production, and they have not been linked to the same degree of fracture risk. Antacids provide quick, short-term relief. Lifestyle modifications — elevating the head of the bed, avoiding meals within three hours of lying down, reducing alcohol and caffeine, losing weight — can resolve mild reflux entirely. The tradeoff is real: these approaches require more effort and more patience than swallowing a daily pill. But for an older adult whose bones and brain are already under siege from aging, the math favors the harder path. Ask any geriatrician whether they would keep a 75-year-old dementia patient on omeprazole for vague dyspepsia, and the answer is almost universally no. The legal history of PPI lawsuits reveals how seriously courts and patients have taken these risks. As of February 2026, 11,322 active cases remain pending in MDL 2789 in federal court in New Jersey, with 18,706 people in the U.S. having filed lawsuits against PPI manufacturers. The majority of current claims center on kidney damage, but bone fracture claims were part of earlier litigation. In October 2023, AstraZeneca announced a $425 million settlement to resolve most Nexium and Prilosec claims in the New Jersey MDL. An earlier bone-fracture-specific multidistrict litigation, MDL 2404, focused on Nexium bone injury cases but was dismissed after a judge questioned the reliability of expert testimony. That MDL closed on January 4, 2017. The dismissal did not mean PPIs were safe for bones — it meant the legal standard for proving causation in court is higher than the scientific standard for identifying a concerning association. The FDA warning, the meta-analyses, and the 2025 reviews all point in the same direction. The absence of a successful bone-fracture lawsuit does not erase the clinical evidence. It simply means the legal system and the medical evidence have not yet fully aligned on this particular harm. If you are caring for someone with cognitive decline who is also taking a PPI, bring the medication to the next appointment and ask three direct questions. First: is there a documented, current indication for this PPI, or was it started years ago and never revisited? Second: has anyone checked this person’s calcium, magnesium, vitamin B12, and bone density recently? Third: what would a supervised taper look like, and is it safe to try? Many physicians will appreciate the prompt — deprescribing PPIs in elderly patients is increasingly recognized as good practice, but it often falls through the cracks in busy clinical settings. A 2025 umbrella review published in ScienceDirect confirmed the osseous implications of PPI therapy across multiple meta-analyses, reinforcing that this is not a fringe concern but a mainstream one that warrants active management. The most honest thing to say about PPI fracture research is that randomized controlled trials specifically designed to test whether PPIs cause fractures are still lacking. The evidence base remains observational, which means we can say with confidence that PPI use is associated with increased fracture risk, but proving direct causation under the strictest scientific standards has not yet been achieved. A 2025 meta-analysis published in Frontiers in Pharmacology found a pooled risk ratio of 1.20 for short-term PPI use and 1.24 for long-term use of three years or more, adding to the accumulating weight of evidence. As the U.S. population ages and dementia prevalence rises, expect growing pressure from geriatricians and public health researchers to either conduct definitive trials or to shift prescribing guidelines more aggressively toward deprescribing PPIs in older adults. The $19.99 billion the U.S. spent on PPIs in 2016-2017 represents an enormous financial incentive to keep these drugs flowing, which makes the scientific and regulatory pushback all the more important. Proton pump inhibitors are effective drugs with legitimate uses, but their massive overprescription has created a slow-moving fracture epidemic among older adults — the very population least equipped to survive a broken hip or spine. The numbers are stark: a 45 percent increase in hip fracture risk, a 60 percent increase in spine fracture risk, and tens of millions of prescriptions written every year for people who may not need them. For families navigating dementia, the stakes are compounded. A fracture does not just threaten mobility; it threatens cognition, independence, and life itself. The path forward is not complicated, but it requires action. Review the medication list. Ask whether the PPI is still necessary. Request bone density and nutrient testing. Explore alternatives. Work with a physician on a taper if appropriate. These are small steps that can prevent devastating outcomes. No one should break a hip because of a pill they did not need for heartburn they could have managed another way. The FDA’s review found the highest risk in patients using PPIs for one year or more, though some studies identified elevated risk with shorter durations. A 2025 meta-analysis found a pooled risk ratio of 1.20 even for short-term use, suggesting there may not be a perfectly safe window. No. The FDA’s 2010 warning applied to both prescription and OTC PPIs. The active ingredients are the same — omeprazole sold over the counter is chemically identical to prescription omeprazole. OTC packaging recommends 14-day courses, but many people use them continuously for months or years without medical oversight. Calcium supplementation is reasonable, but it does not fully solve the problem. PPIs impair the stomach’s ability to absorb calcium in the first place, so simply taking more calcium may not be efficiently utilized. Calcium citrate is generally better absorbed than calcium carbonate in low-acid conditions. Vitamin D should be taken alongside calcium, and magnesium and B12 levels should also be monitored. Do not stop abruptly. Sudden discontinuation can cause rebound acid hypersecretion that is extremely uncomfortable and may lead to resuming the drug at a higher dose. Work with the prescribing physician on a gradual taper, possibly stepping down to an H2 blocker like famotidine during the transition. The evidence for H2 blockers and fracture risk is much weaker than for PPIs. H2 blockers reduce acid production less aggressively and do not appear to impair calcium absorption to the same degree. For mild to moderate reflux symptoms, they represent a meaningfully safer option for bone health, though they are less effective for severe acid-related conditions.
What the FDA Warning Actually Says — and What It Leaves Out
The Dementia Connection — Why PPI-Related Fractures Hit Harder in Aging Brains
Safer Alternatives and How to Weigh the Tradeoffs
The Litigation Landscape and What It Tells Us About Risk
What Caregivers Should Ask at the Next Doctor’s Visit
Where the Science Is Headed
Conclusion
Frequently Asked Questions
How long do you have to take a PPI before fracture risk increases?
Are over-the-counter PPIs safer than prescription PPIs for bone health?
Can calcium supplements offset the bone damage from PPIs?
My parent has dementia and has been on Prilosec for five years. Should I stop it immediately?
Are H2 blockers like famotidine linked to the same fracture risk?
You Might Also Like
